May 2014 Issue of The Ophthalmologist

Certain patients don't get the treatment that they need. A little understanding and forward planning can solve the problem.

Actually, it's 1,000 shades – that’s what the human eye can discriminate in adapting to bright and dark condition. How does glaucoma affect this ability?

To shave $2.7 billion from costs there will be substantial cuts and job losses

Around since the 1950s, it has now been proven to improve visual outcomes in patients with idiopathic intracranial hypertension

If you had your time again, would you go to medical school, and would you choose ophthalmology?

A three-year study of progressive keratoconus has shown that corneal cross-linking is associated with sustained delay in disease progression.

Uveal and skin melanoma originate in the same type of cell, but are very different in terms of molecular mechanism, pathobiology, prognosis and therapeutic strategy. Here, the features of uveal melanoma are described and the latest therapeutic developments discussed.

People with learning disabilities are ten times more likely to have serious sight problems than the general population and often fail to receive the same standard of care. Here’s how to avoid some of the pitfalls and some tips for a successful doctor-patient relationship.

A new technology that measures subjective refraction based on point spread function targets generates better data, increases efficiency in the clinic and improves patient outcomes.

Increasing the light intensity over the thinnest point of the cornea – the periphery –improves outcomes of corneal collagen cross-linking in keratectasia patients.

What does analysis of the last five years of the literature on Stargardt Disease tell us about the priorities of the field and the major contributors to it?

The concept of using photoactivated chromophores for corneal cross-linking (PACK-CXL) as a weapon against infectious keratitis is compelling. The evidence suggests that PACK-CXL could have a dramatic impact on a major cause of global blindness… but only if the expensive, bulky technology (and the requirement for a corneal surgeon in a sterile operating theater) can be overcome. One company may have the answer.

The development and use of intraocular lenses has been a major ophthalmic success story. Here, we describe some of the key contributions and the materials that revolutionized cataract treatment.

Sitting Down With Alice McPherson,founder of the Retina Research Foundation